HDAC1 and renal dialysis: Additionally, the mesothelial cells (MCs) isolated from effluent of peritoneal dialysis (PD) patients were treated with MS-275, a HDAC1–3 inhibitor, and downregulated mesenchymal markers including TGF-β1 to promote EMT reversal.